Chronic Inflammation and Coronary Atherosclerosis in Patients with End-Stage Renal Disease

Overview

Journal Cardiorenal Med

Publisher Karger

Specialties Cardiology & Vascular Diseases
Endocrinology
Nephrology

Date 2012 Aug 2

PMID 22851960

Citations 28

Authors

Maen B Nusair

Naveen Rajpurohit

Martin A Alpert

Affiliations

Soon will be listed here.

Abstract

The key role of chronic inflammation in the pathogenesis of atherosclerosis has become increasingly apparent in recent years based on the results of experimental, epidemiologic and clinical studies. Coronary artery disease and its complications occur with disproportionately high frequency in patients with end-stage renal disease (ESRD) and contribute substantially to cardiovascular morbidity and mortality in this population. Traditional cardiovascular risk factors occur commonly in patients with ESRD. In addition, a variety of patient-related and dialysis-related factors unique to ESRD predispose to chronic inflammation and by doing so are thought to contribute to coronary atherosclerosis and its complications. These risk factors may serve as therapeutic targets and as such may offer the potential for altering the natural history of coronary atherosclerosis in ESRD.

Citing Articles

Global prevalence and contributing factors of transplant renal artery stenosis in renal transplant recipients: A systematic review and meta-analysis.

Tamara F, Fajar J, Gersom C, Wicaksono R, Tupamahu A, Huda F Narra J. 2025; 4(3):e1782.

PMID: 39816090 PMC: 11731806. DOI: 10.52225/narra.v4i3.1782.

Severe Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Patients on Chronic Hemodialysis-Reconsidering the Relationship with Thrombo-Inflammation and Oxidative Stress.

Nikolovski S, Medic Brkic B, Savic Vujovic K, Cirkovic I, Jovanovic N, Reddy B Diagnostics (Basel). 2024; 14(21).

PMID: 39518373 PMC: 11544906. DOI: 10.3390/diagnostics14212406.

Thromboinflammatory Biomarkers of Cardiorenal Syndrome in Patients With End-Stage Renal Disease.

Karumanchi P, Sridharan D, Hoppensteadt D, Siddiqui F, Fareed J, Bansal V Clin Appl Thromb Hemost. 2024; 30:10760296241263101.

PMID: 38863224 PMC: 11179552. DOI: 10.1177/10760296241263101.

The neutrophil percentage-to-albumin ratio is an independent risk factor for poor prognosis in peritoneal dialysis patients.

Xu M, Huan J, Zhu L, Xu J, Song K Ren Fail. 2024; 46(1):2294149.

PMID: 38178381 PMC: 10773631. DOI: 10.1080/0886022X.2023.2294149.

Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease.

Lin W, Mousavi F, Blum B, Heckendorf C, Moore J, Lampl N Front Pharmacol. 2023; 14:1243505.

PMID: 38089059 PMC: 10715419. DOI: 10.3389/fphar.2023.1243505.

References

McIntyre C, Harrison L, Eldehni M, Jefferies H, Szeto C, John S . Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol. 2010; 6(1):133-41. PMC: 3022234. DOI: 10.2215/CJN.04610510. View

Yeun J, Levine R, Mantadilok V, Kaysen G . C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35(3):469-76. DOI: 10.1016/s0272-6386(00)70200-9. View

Scirica B, Morrow D . Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation. 2006; 113(17):2128-34. DOI: 10.1161/CIRCULATIONAHA.105.611350. View

Xu Q . Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol. 2002; 22(10):1547-59. DOI: 10.1161/01.atv.0000029720.59649.50. View

Cheung A, Sarnak M, Yan G, Berkoben M, Heyka R, Kaufman A . Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int. 2004; 65(6):2380-9. DOI: 10.1111/j.1523-1755.2004.00657.x. View

Janeway Jr C, Medzhitov R . Innate immune recognition. Annu Rev Immunol. 2002; 20:197-216. DOI: 10.1146/annurev.immunol.20.083001.084359. View

Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B . Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6?. Kidney Int Suppl. 2002; (80):103-8. DOI: 10.1046/j.1523-1755.61.s80.19.x. View

Binder C, Hartvigsen K, Chang M, Miller M, Broide D, Palinski W . IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest. 2004; 114(3):427-37. PMC: 484976. DOI: 10.1172/JCI20479. View

Folsom A, Pankow J, Tracy R, Arnett D, Peacock J, Hong Y . Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol. 2001; 88(2):112-7. DOI: 10.1016/s0002-9149(01)01603-4. View

10.

Stenvinkel P, Heimburger O, Jogestrand T . Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis. 2002; 39(2):274-82. DOI: 10.1053/ajkd.2002.30546. View

11.

Habib A, Baird B, Leypoldt J, Cheung A, Goldfarb-Rumyantzev A . The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant. 2006; 21(10):2881-92. DOI: 10.1093/ndt/gfl272. View

12.

Dai G, Kaazempur-Mofrad M, Natarajan S, Zhang Y, Vaughn S, Blackman B . Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. Proc Natl Acad Sci U S A. 2004; 101(41):14871-6. PMC: 522013. DOI: 10.1073/pnas.0406073101. View

13.

Mach F, Schonbeck U, Bonnefoy J, Pober J, Libby P . Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997; 96(2):396-9. DOI: 10.1161/01.cir.96.2.396. View

14.

Ridker P, Buring J, Shih J, Matias M, Hennekens C . Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998; 98(8):731-3. DOI: 10.1161/01.cir.98.8.731. View

15.

Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B . Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003; 41(6):1212-8. DOI: 10.1016/s0272-6386(03)00353-6. View

16.

Shlipak M, Fried L, Crump C, Bleyer A, Manolio T, Tracy R . Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003; 107(1):87-92. DOI: 10.1161/01.cir.0000042700.48769.59. View

17.

Carrero J, Stenvinkel P . Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol. 2009; 4 Suppl 1:S49-55. DOI: 10.2215/CJN.02720409. View

18.

Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C . Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int. 2008; 74(11):1461-7. DOI: 10.1038/ki.2008.484. View

19.

Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G . Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000; 15(2):218-23. DOI: 10.1093/ndt/15.2.218. View

20.

Galis Z, Sukhova G, Lark M, Libby P . Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994; 94(6):2493-503. PMC: 330083. DOI: 10.1172/JCI117619. View